Press Release

Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine

SAN DIEGO, CA / ACCESSWIRE / September 18, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that they were named one of the "50 Most Trustworthy Companies of the Year" for 2019 by The Silicon Review magazine.…
Calidi Biotherapeutics
September 17, 2019
Press Release

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

SAN DIEGO, CA / ACCESSWIRE / August 29, 2019 / Calidi Biotherapeutics Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer announced today, the completion of the adipose tissue collection from healthy donors necessary for isolation of adipose-derived mesenchymal stem cells (AD-MSC) -…
Calidi Biotherapeutics
August 29, 2019
Press Release

Calidi Biotherapeutics Announces the Appointment of Distinguished Biotech Innovator, Ewa Carrier, M.D., to Their Medical and Scientific Advisory Board

Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of a distinguished innovator in the field of cancer diagnosis and treatment, Ewa Carrier, MD, to their medical and scientific advisory board. Dr. Carrier has…
Press Release

Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field

SAN DIEGO, CA / ACCESSWIRE / July 10, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of stem cell-based delivery of oncolytic virus-based immunotherapies for cancer, today announced an exclusive veterinary worldwide license for the development and commercialization of its lead…
Press Release

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

SAN DIEGO (PRWEB) JUNE 03, 2019 - Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of Dr. Dmitriy Zamarin, MD, Ph.D., to their scientific advisory board. Dr. Zamarin is an accomplished medical oncologist who…
Press Release

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

SAN DIEGO, May 30, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive: Dr. Ashok Srivastava, MD, Ph.D., MBA, to their scientific advisory board. Dr. Srivastava's notable achievements include contributions to…
Press Release

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

SAN DIEGO, May 28, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced their ongoing scientific collaboration with David F. Stroncek, M.D., Chief, Cell Therapy Section at the Department of Transfusion Medicine, National Institutes of Health (NIH)…